Spinal Muscular Atrophy | ASGCT - American Society of Gene & Cell Therapy |

<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml"> <head>  <script type="text/javascript">(function (w, d, s, l, i) { w[l] = w[l] || []; w[l].push({ 'gtm.start': new Date().getTime(), event: 'gtm.js' }); var f = d.getElementsByTagName(s)[0], j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f); })(window, document, 'script', 'dataLayer', 'GTM-NFW5DS9');</script>   <script type="text/javascript"> //------------------------------------------------------- var z_account = "2632C1D8-6432-4D3A-93D6-08AAECC53F86"; var z_collector = "asgct.informz.net"; var z_cookieDomain = ".asgct.org"; //------------------------------------------------------- (function (e, o, n, r, t, a, s) { e[t] || (e.GlobalSnowplowNamespace = e.GlobalSnowplowNamespace || [], e.GlobalSnowplowNamespace.push(t), e[t] = function () { (e[t].q = e[t].q || []).push(arguments) }, e[t].q = e[t].q || [], a = o.createElement(n), s = o.getElementsByTagName(n)[0], a.async = 1, a.src = r, s.parentNode.insertBefore(a, s)) }(window, document, "script", "https://cdn.informz.net/web_trk/sp.js", "informz_trk")), informz_trk("newTracker", "infz", z_collector + "/web_trk/collector/", { appId: z_account, cookieDomain: z_cookieDomain }), informz_trk("setUserIdFromLocation", "_zs"), informz_trk("enableActivityTracking", 30, 15); informz_trk("trackPageView", null); </script>  <meta charset="utf-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="viewport" content="width=device-width,user-scalable=no,maximum-scale=1.0,initial-scale=1.0" /> <link href="/BlueKey/pe_assets/build/styles.css" rel="stylesheet" /> <script type="text/javascript" defer="defer" src="https://extend.vimeocdn.com/ga/127349852.js"></script> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="https://twitter.com/ASGCTherapy" <meta name="twitter:creator" content="@ASGCTherapy" <meta name="twitter:title" content="Gene Therapy and Spinal Muscular Atrophy" <meta name="twitter:description" content="Gene therapy is a fitting approach for diseases caused by a single gene mutation, like SMA. It targets the cause of disease by delivering a fully functioning copy of the gene into motor neuron cells. Let’s learn more about how it works." <meta name="twitter:image" content="~1d8ac6fd-ad1b-46f5-bc27-2ce8df05434e/attachment.aspx" <meta name="description" content="Spinal Muscular Atrophy (SMA) is a rare genetic disease that affects the motor nerve cells in the spinal cord and is the leading genetic cause of infant mortality." /> <meta charset="UTF-8" /> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="shortcut icon" /> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="icon" /> <title> Spinal Muscular Atrophy | ASGCT - American Society of Gene & Cell Therapy | </title></head> <body class="LTR IE IE7 ENUS ContentBody">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NFW5DS9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <form method="post" action="/disease-treatments/sma" id="aspnetForm"> <div class="aspNetHidden"> <input type="hidden" name="__CMSCsrfToken" id="__CMSCsrfToken" value="Nqhp4rtZoJXAeprCtEtrMwcedXyem00fEpT+rtDCh0dkMZlhwMTYmrt4bXEqTijrgYP4rY5mfgfRRS5Gux/lfaGvSXs=" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=UZQNzmZXG1IdUaHxtavOjRvGEvOmz1kvw97PqEaxzBy7Ys-tUotw-RqgdbsvC3g_7cXjehqAdA_N6kbuK73WBAVGdxo1&t=638562384440000000" type="text/javascript"></script> <input type="hidden" name="lng" id="lng" value="en-US" /> <script type="text/javascript"> //<![CDATA[ function PM_Postback(param) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); } if(window.CMSContentManager) { CMSContentManager.allowSubmit = true; }; __doPostBack('ctl00$CMSPortalManager1$am',param); } function PM_Callback(param, callback, ctx) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); }if (window.CMSContentManager) { CMSContentManager.storeContentChangedStatus(); };WebForm_DoCallback('ctl00$CMSPortalManager1$am',param,callback,ctx,null,true); } //]]> </script> <script src="/ScriptResource.axd?d=WTJtoz6EJe-loUBJ9stbRxqzgpVp8oo0KdZGkhGfcu6Lr7kb5LeNfx21FKi8mxEL1oDZOLAxiAqERpClgBx-A6lZ0DJ1qKcDZB1NuIbRd8o9S7aG0&t=7c776dc1" type="text/javascript"></script> <script src="/ScriptResource.axd?d=y6KGkkRaceYF_mkApXCXMQ_rMQVX59BlJ-ut-lQDHw88bR5bbS86epdVNwimj01duE6_OophLX4sBTOgb8_5dNLaY2Mx5DHMJj7Rbr4kPMV1-AOS5VF5-QEC8oG-_-aHoWoyqA2&t=7c776dc1" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var CMS = CMS || {}; CMS.Application = { "isDialog": false, "isDebuggingEnabled": false, "applicationUrl": "/", "isRTL": "false", "imagesUrl": "/CMSPages/GetResource.ashx?image=%5bImages.zip%5d%2f" }; //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2CD64FB1" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAMDDaQ6LJ2Y4TBhi/zYU8wQDMN6QAizBz4KoPbUd79oAZD1NQdfl/cWuar5Vh7dGPTNEUkUjLlfR5mlTWKUcjZOPeJklA==" /> </div> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$manScript', 'aspnetForm', ['tctl00$ctxM',''], [], [], 90, 'ctl00'); //]]> </script> <div id="ctl00_ctxM"> </div> <header class="c-header"> <a href="#content" class="show-on-focus">Skip to main content</a> <div class="c-header-utilities"> <div class="container"> <div class="columns is-vcentered"> <div class="column"> <a href="https://asgct.org" class="is-external">ASGCT.org</a> </div> <div class="column is-half"> <a href="/"> <div class="c-header-images"> <div class="c-header-image"> <img src="/PatientEducation/media/PatientEducation/ASGCT_Web_Horz_Navy.png?ext=.png" alt="" /> </div> <div class="c-header-image"> <img src="/PatientEducation/media/PatientEducation/temp-pe-logo.png?ext=.png" alt="Patient Education Logo" /> </div> </div> </a> </div>  <div class="column"> <div class="c-header-search"> <div class="c-header-search-wrap"> <input name="keyword" type="text" id="searchtext" placeholder="Search" aria-required="false" /> <label for="searchtext" class="is-sr-only">Keyword search</label> <button type="button" data-encode="searchtext" data-path="/search-results" data-query="searchtext"> <span class="is-sr-only">Search</span> <span class="c-search-icon"></span> </button> </div> </div> </div> </div> </div> </div> <div class="c-header-utilities-mobile"> <div class="c-header-images"> <div class="c-header-image"> <a href="https://asgct.org" class="is-external"><img src="/PatientEducation/media/PatientEducation/ASGCT_Web_Horz_Navy.png?ext=.png" alt="" /></a> </div> <div class="c-header-image"> <a href="/"><img src="/PatientEducation/media/PatientEducation/temp-pe-logo.png?ext=.png" alt="Patient Education Logo" /></a> </div> </div> <button class="c-nav-toggle" type="button" aria-controls="c-nav-main" aria-expanded="false" data-togglevisibility="data-togglevisibility"> <p class="is-sr-only">Open Navigation</p> <p class="is-sr-only" aria-hidden="true">Close Navigation</p> <span class="c-nav-toggle-menu"></span> </button> </div> <div id="ctl00_plcMain_bkSiteHeader_headerBanner"> <div class="header-alert"> <div class="container"> <p id="ctl00_plcMain_bkSiteHeader_pBanner"><b><a href="https://patienteducation.asgct.org/newsletter/subscribe-to-the-patient-press">Subscribe today to ASGCT's patient-centered newsletter, The Patient Press!</a></b></p> </div> </div> </div> <nav class="c-nav-main" id="c-nav-main" aria-hidden="true"> <div class="container"> <div class="c-header-search is-hidden-desktop"> <div class="c-header-search-wrap"> <input name="" type="text" id="global-search" placeholder="Search" aria-required="false" /> <label for="global-search" class="is-sr-only">Keyword search</label> <button type="button" data-encode="global-search" data-path="/search-results" data-query="searchtext"> <span class="is-sr-only">Search</span> <span class="c-search-icon"></span> </button> </div> </div> <ul> <li> <a href="/gene-therapy-101">Gene & Cell Therapy 101</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/gene-therapy-101/gene-therapy-basics">Gene Therapy Basics</a> </li> <li> <a href="/gene-therapy-101/cell-therapy-basics">Cell Therapy Basics</a> </li> <li> <a href="/gene-therapy-101/gene-therapy-approaches">Gene Therapy Approaches</a> </li> <li> <a href="/gene-therapy-101/gene-editing">Gene Editing</a> </li> <li> <a href="/gene-therapy-101/clinical-trials">Clinical Trials</a> </li> <li> <a href="/gene-therapy-101/vectors-101">Vectors 101</a> </li> <li> <a href="/gene-therapy-101/glossary">Glossary</a> </li> <li> <a href="/gene-therapy-101/covid19-vaccines">COVID-19</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/disease-treatments">Condition Treatments</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/disease-treatments/fda-approved-cell-gene-therapy-products">FDA-Approved Cell & Gene Therapy Products</a> </li> <li> <a href="/disease-treatments/batten">Batten Disease</a> </li> <li> <a href="/disease-treatments/blood-disorders">Beta Thalassemia & Other Blood Disorders</a> </li> <li> <a href="/disease-treatments/leukodystrophy">CALD and MLD</a> </li> <li> <a href="/disease-treatments/car-t-basics">CAR-T Basics</a> </li> <li> <a href="/disease-treatments/fabry">Fabry Disease</a> </li> <li> <a href="/disease-treatments/gaucher-disease">Gaucher Disease</a> </li> <li> <a href="/disease-treatments/gm1-gangliosidosis">GM1 Gangliosidosis</a> </li> <li> <a href="/disease-treatments/gm2-tay-sachs-sandhoff">Tay-Sachs and Sandhoff Disease</a> </li> <li> <a href="/disease-treatments/hemophilia">Hemophilia</a> </li> <li> <a href="/disease-treatments/huntingtons-disease">Huntington's Disease</a> </li> <li> <a href="/disease-treatments/inherited-retinal-diseases">Inherited Retinal Diseases</a> </li> <li> <a href="/disease-treatments/mps">Mucopolysaccharidoses (MPS)</a> </li> <li> <a href="/disease-treatments/muscular-dystrophy">Muscular Dystrophy</a> </li> <li> <a href="/disease-treatments/pompe-disease">Pompe Disease</a> </li> <li> <a href="/disease-treatments/parkinsons-disease">Parkinson's Disease</a> </li> <li> <a href="/disease-treatments/sickle-cell-disease">Sickle Cell Disease</a> </li> <li> <a href="/disease-treatments/sma">Spinal Muscular Atrophy</a> </li> <li> <a href="/disease-treatments/wilson-disease">Wilson Disease</a> </li> <li> <a href="/disease-treatments/xlmtm">X-Linked Myotubular Myopathy</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/patient-journey">Patient Journey</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/patient-journey/identifying-a-genetic-disease">Identifying a Genetic Disease</a> </li> <li> <a href="/patient-journey/next-steps-with-a-diagnosis">Next Steps With a Diagnosis</a> </li> <li> <a href="/patient-journey/patient-focused-policy-positions">Patient-Focused Policy Positions</a> </li> <li> <a href="/patient-journey/stimulating-research">Stimulating Research</a> </li> <li> <a href="/patient-journey/considering-a-clinical-trial">Considering a Clinical Trial</a> </li> <li> <a href="/patient-journey/ethical-issues-germline-gene-editing">Ethical Issues: Germline Gene Editing</a> </li> <li> <a href="/patient-journey/ethical-issues-illegitimate-clinical-trials">Ethical Issues: Unproven Stem Cell Products</a> </li> <li> <a href="/patient-journey/gene-therapy-centers">Gene Therapy Centers</a> </li> <li> <a href="/patient-journey/clinical-trials-finder">Clinical Trials Finder</a> </li> <li> <a href="/patient-journey/on-demand">On Demand Webinars</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/newsletter">Newsletter</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/newsletter/subscribe-to-the-patient-press">Subscribe to The Patient Press</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/quick-takes">Quick Takes</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/quick-takes/focused-ultrasound-in-cell-and-gene-therapies">Focused Ultrasound in CGTs</a> </li> <li> <a href="/quick-takes/access-to-approved-cell-and-gene-therapies">Access to Approved CGTs</a> </li> <li> <a href="/quick-takes/informed-consent">Informed Consent</a> </li> <li> <a href="/quick-takes/state-of-the-field-cgt-highlights-and-approvals-20">State of the Field: CGT Highlights and Approvals of 2023</a> </li> <li> <a href="/quick-takes/genetic-testing-and-clinical-trial-eligibility">Genetic Testing and Clinical Trial Eligibility</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/events">Events</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/events/empowering-patients-2025-a-cell-and-gene-therapies">Empowering Patients 2025: A Cell and Gene Therapies Summit</a> </li> <li> <a href="/events/annual-meeting-patient-advocate-offerings">Annual Meeting-Patient Advocate Offerings</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/about-asgct">About</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/about-asgct/overview">Overview</a> </li> <li> <a href="/about-asgct/about-asgct">About ASGCT</a> </li> <li> <a href="/about-asgct/news">ASGCT News</a> </li> <li> <a href="/about-asgct/privacy-policy">Privacy Policy</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/support">Support</a> </li> </ul> <a href="asgct.org" class="px-1 is-external is-hidden-desktop">ASGCT.org</a> </div> </nav> <div class="c-banner" style="background: url('/getattachment/Disease-Treatments/SMA/GM2-2.PNG.aspx') 50%/cover no-repeat;"> <div class="c-banner-content container"> <h1>Spinal Muscular Atrophy</h1> </div> </div> </header> <main class="c-main" id="content"> <section class="c-breadcrumbs"> <div class="container"> <span><a href="/">Home</a> > </span> <a href="/disease-treatments" title="Condition Treatments" class="CMSBreadCrumbsLink">Condition Treatments</a> > <span class="CMSBreadCrumbsCurrentItem">Spinal Muscular Atrophy</span> </div> </section> <section class="section"> <div class="container"> <div class="columns"> <div class="column is-8"> <div class="c-leader"> </div> <div class="content mb-6"> <p>Spinal Muscular Atrophy (SMA) is a rare genetic disease that affects the motor nerve cells in the spinal cord and is the leading genetic cause of infant mortality. It is caused by an inherited faulty SMN1 gene. The SMN1 gene helps provide instructions to cells on how to produce the SMN (survival motor neuron) protein. If there isn’t enough correct SMN protein produced, it leads to degeneration, meaning decline or deterioration, of motor neurons. This creates problems with a person’s physical strength, often taking away the ability to walk, eat or even breathe. Gene therapy is a fitting approach for diseases caused by a single gene mutation, like SMA. It targets the cause of disease by delivering a working fully functioning copy of the gene into motor neuron cells. Let’s learn more about how it works.</p> <p><iframe type="text/html" width="640" height="385" src="//www.youtube.com/embed/1W5xRCwmcRA?fs=1&enablejsapi=1&version=3" frameborder="0" allowfullscreen="allowfullscreen"></iframe> </p> <p><b>Watch our </b><strong><a href="https://asgct.org/events/sma-lunch" target="_blank">Lunch & Learn: Gene Therapy for SMA</a> event on YouTube!</strong></p> <p><a class="c-button-primary" href="https://www.youtube.com/watch?v=YFEMR1ZHYFc" target="_blank">Watch On Demand</a></p> <h2>Treatments</h2> <p><a href="https://www.asgct.org/ASGCT/media/about/SMA-Infographic.pdf" target="_blank"><img alt="" src="https://asgct.org/getmedia/2f2e1e3c-86de-43ac-bc06-6faf9fd9b8d9/SMA-infographic.aspx?width=350&height=350" style="width: 350px; height: 350px; float: right; margin: 5px 10px;" /></a></p> <p paraeid="{cd54c351-df68-48e7-8f1c-169fb91a7a72}{32}" paraid="615384298">There are a few approved gene therapy treatment options available that can help manage symptoms of SMA, along with slowing or stopping disease progression. There are also active preclinical research studies and clinical trials for SMA, including those studying to expand existing treatments for more ages or investigating dual treatments. <a href="https://patienteducation.asgct.org/gene-therapy-101/clinical-trials-process" rel="noreferrer noopener" target="_blank">Clinical trials</a><a href="/gene-therapy-101/clinical-trials-process" target="_blank"> </a>are a required part of the research process that aim to help researchers understand the way a drug or treatment will interact with the human body and whether it is safe and effective. Preclinical studies are an even earlier stage of research to confirm the safety and effectiveness of a treatment in animal or cell-based models before proceeding with a human clinical trial.  </p> <p paraeid="{cd54c351-df68-48e7-8f1c-169fb91a7a72}{75}" paraid="1124022684">To stay up to date on open clinical trials in the U.S. or globally, visit the <a href="https://app.emergingmed.com/asgct/home/%22%20/t%20%22_blank" rel="noreferrer noopener" target="_blank">ASGCT Clinical Trials Finder</a> and search Spinal Muscle Atrophy using the "diagnosis" filter.  </p> <h3>Zolgensma </h3> <p>The FDA approved Zolgensma is a gene therapy developed by Novartis Gene Therapies for clinical use in the United States with children under two years of age with all types of SMA.</p> <p><a href="http://www.zolgensma.com/?gclid=Cj0KCQjwuLPnBRDjARIsACDzGL2lcIZUm-kjZcKvAk8CVaRukjQ7MDGr1wWwNIx-7-kB809nN52n3VQaAntMEALw_wcB" target="_blank">Learn More About Zolgensma</a></p> <p>For clinical trials treating SMA type 1, researchers described improvements in respiratory and movement function meaning patients were able to breathe better, feed themselves, and sit unassisted. These improvements lead to fewer and less lengthy hospitalizations compared to what patients traditionally face. These reductions in hospitalizations can help improve both the child’s and caregiver’s quality of life.</p> <h3>Spinraza</h3> <p>There’s an FDA-approved treatment called <a href="https://www.spinraza.com/" target="_blank">Spinraza</a> that helps to counter the effects of SMA. Spinraza helps increase the production of the SMN protein by using a backup gene called SMN2. With Spinraza’s help, enough SMN protein is produced. If you think this treatment might be an option for you or your child, make an appointment with your healthcare provider to learn more and help determine eligibility.</p> <h2>Challenges & Benefits</h2> <h3>One-Time Treatment and Expansion</h3> <p>The aim for SMA gene therapy is to only need one administration by targeting the cause of the disease. Typically this should only take about an hour. This is in comparison to other treatments that may require a series of doses, multiple times throughout the patient’s life. Once a therapy is approved, then researchers begin to work on expanding it to reach patients that have other Types of SMA or that may be older than the current inclusion age.</p> <h3>Early Diagnosis: Newborn Screenings</h3> <p>The symptoms of SMA Type 1—the most common and severe form of the disease—show up within the first six months of a child’s life. These symptoms can cause irreversible damage to a patient within this period, so early diagnosis is key to receiving an effective gene therapy treatment.</p> <p>Early diagnosis can be completed through standard newborn screenings. Although progress has been made, there are still many states that do not include SMA as a part of standard screening completed for newborns. As mentioned above, it is highly important for this disease to be diagnosed as early as possible. You can <a href="http://www.curesma.org/get-involved/advocacy/" target="_blank">help advocate for SMA</a> to be added to the panel of newborn screenings in your state.</p> <h3>Screening Before or During Pregnancy</h3> <p>Parents who are planning a pregnancy can learn if they are carrying genes for inherited disorders by analyzing small samples of blood or body tissues gathered from a cheek swab or blood draw. Expecting parents can also consider genetic testing during pregnancy, where pregnant women can undergo amniocentesis or chorionic villus sampling to screen for disorders. Genetic testing can also be done soon after birth.</p> <h3>Eligibility and Access</h3> <p>If you are considering participation in a clinical trial for yourself or your child, remember that it is difficult to know if and when a clinical trials can be stopped, delayed or approved. Because of this, it can be risky to avoid other forms of care or approved treatments while waiting for a new treatment approval. It is also important to know that certain eligibility criteria is in place, which may include age or weight, and having a certain type of SMA. It is best to speak with your healthcare provider or neurologist to understand and maneuver this difficult decision-making process.</p> <h3>Patient and Family Support</h3> <p>Patient advocacy organizations work hard to provide support, advice and information for getting involved. They are a great way to connect with other families affected by SMA. Although the disease may be rare, you’re not alone. For more resources and support networks, check out:</p> <ul> <li><a href="http://www.curesma.org/" target="_blank">CureSMA</a></li> <li><a href="http://www.sma-europe.eu/" target="_blank">SMA Europe</a></li> <li><a href="https://www.fightingforkaiden.org/kaidensstory.html" target="_blank">Fighting for Kaiden Foundation</a></li> <li><a href="https://www.laughingatmynightmare.com/" target="_blank">Laughing at My Nightmare</a></li> <li><a href="https://www.wecarrykevan.com/" target="_blank">We Carry Kevan</a></li> </ul> <p>You can also watch this series of webinars from NORD, <a href="http://createsend.com/t/j-CED19B31AAF073232540EF23F30FEDED" target="_blank">Obtaining Support and Ongoing Care for Children with Spinal Muscular Atrophy (SMA) After Gene Replacement Therapy</a>, a six-part educational program intended for caregivers and patients affected by SMA. You'll hear from experts who will discuss the benefits of gene replacement therapy and methods to maintain respiratory health, improve motor function, and optimize nutritional health for patients with SMA.</p> <h3>Cure vs. Control</h3> <p>While pursuing existing or future SMA gene therapy treatments, it is important to note that gene therapy is not a cure and instead helps to control the progression of the disease. It’s impossible to restore already damaged neurons in a patient. However, gene therapy can help slow or stop the effects of the disease, greatly increasing the quality of life for the child as they grow older.</p> </div> </div> <div class="column is-4 pl-4"> <div class="c-nav-local-wrap"> <div class="asideBox"> <h3> Related Pages</h3> <hr class="is-secondary" /> <ul class="c-nav-local-list"> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/disease-treatments/fda-approved-cell-gene-therapy-products">FDA-Approved Cell & Gene Therapy Products</a> </li> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/disease-treatments/gaucher-disease">Gaucher Disease</a> </li> </ul> </div> </div> </div> </div> </div> <div class="lastUpdatedTag"> <p>Last Updated: 08/18/2022</p> </div> </section> </main> <footer class="c-footer"> <div class="c-footer-primary"> <section class="section"> <div class="container"> <div class="columns"> <div class="column c-footer-section"> <p><img alt="" src="/PatientEducation/media/PatientEducation/logo_white.png" /></p> <p>20800 Swenson Dr., Suite 300<br /> Waukesha, WI 53186</p> </div> <div class="column is-two-fifths c-footer-section"> <ul class="c-utility-list"> <li><a href="#">Gene Therapy 101</a></li> <li><a href="#">Disease Treatments</a></li> <li><a href="#">Clinical Trials</a></li> <li><a href="/patient-journey">Patient Journey</a></li> <li><a href="/about-asgct">About</a></li> <li><a href="/support">Support</a></li> <li><a href="https://asgct.org/about/privacy-policy" target="_blank">Privacy Policy</a></li> </ul> </div> <div class="column c-footer-section"> <h3 class="mb-3">Connect with ASGCT</h3> <p class="mb-0"><span>Phone: 414</span>.278.1341</p> <p><a href="mailto:info@asgct.org">info@asgct.org</a></p> <p> <div class="c-social"> <ul class="c-social-list"> <li class="c-social-item"><a href="https://twitter.com/ASGCTherapy" target="_blank" class="c-social-link twitter"><span class="is-sr-only">Twitter</span></a></li> <li class="c-social-item"><a href="https://www.facebook.com/ASGCTherapy" target="_blank" class="c-social-link facebook"><span class="is-sr-only">Facebook</span></a></li> <li class="c-social-item"><a href="https://www.instagram.com/asgctherapy" target="_blank" class="c-social-link instagram"><span class="is-sr-only">Instagram</span></a></li> <li class="c-social-item"><a href="https://www.linkedin.com/company/asgct" target="_blank" class="c-social-link linkedin"><span class="is-sr-only">LinkedIn</span></a></li> <li class="c-social-item"><a href="https://www.youtube.com/user/ASGCT" target="_blank" class="c-social-link youtube"><span class="is-sr-only">YouTube</span></a></li> </ul> </div> </p> </div> </div> </div> </section> </div> <div class="c-footer-secondary"> <section class="section py-4"> <div class="container"> <div class="columns"> <div class="column"> <p class="is-small">© 2024 All rights reserved. American Society of Gene & Cell Therapy.</p> <p class="is-tiny">Web design by <a href="https://www.reasononeinc.com/kentico" target="_blank">Reason One</a>. Powered by <a href="http://www.kentico.com" target="_blank">Kentico</a>.</p> </div> </div> </div> </section> </div> </footer> <div class="CookieConsent"> <span id="ctl00_cookieLawQ_lblText" class="ConsentText">This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.</span> <span class="ConsentButtons"> <input type="submit" name="ctl00$cookieLawQ$btnAllowSpecific" value="OPT OUT" id="ctl00_cookieLawQ_btnAllowSpecific" class="ConsentButton btn btn-default" /> <input type="submit" name="ctl00$cookieLawQ$btnAllowAll" value="ACCEPT" id="ctl00_cookieLawQ_btnAllowAll" class="ConsentButton btn btn-default" /> </span> </div> <script src="/BlueKey/pe_assets/build/main.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var callBackFrameUrl='/WebResource.axd?d=nNME_ObE2oIDm535eYM9xWmIMy-HXBVdo54Ly6sA5tAYPS1aA-gFDzodlP9ijTBRgmjStONrH4-ISuRTp7slHiYkACw1&t=638562384440000000'; WebForm_InitCallback();//]]> </script> </form> </body> </html>

CINXE.COM

Spinal Muscular Atrophy | ASGCT - American Society of Gene & Cell Therapy |